Skip to main content
. 2021 Jan 13;14:379–392. doi: 10.2147/OTT.S288709

Figure 1.

Figure 1

SLC6A14 is increased in active UC and CRC tumor tissues. (A) Bioinformatics analysis of SLC6A14 expression in inflamed mucosal tissues of active UC patients and tumor tissues of CRC patients based on GEO datasets. (B) RT-PCR analysis of SLC6A14 mRNA level in different stages of UC patients. (C) RT-PCR analysis of SLC6A14 expression in CRC tissues and paired non-cancerous tissues. (D) Immunoblot analysis of SLC6A14 protein level in 12 paired of human CRC tissues and adjacent normal colorectal samples. (E) Immunohistochemical analysis of differential SLC6A14 expression in CRC patients. (F) Kaplan–Meier analysis of the association between SLC6A14 expression and overall survival in CRC patients. **P < 0.01 and ***P < 0.001 were considered as significant differences. Bars in all graphs represented mean ± S.D.